Pleynet; David P. M.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Pleynet; David P. M..The latest application filed is for "compounds that modulate intracellular calcium".

Company Profile

0.9.11

Pleynet; David P. M. - Auburndale MA US
Pleynet; David P.M. - San Deigo CA
Pleynet; David P. M. - San Diego CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compounds that modulate intracellular calcium Grant 8,524,765 - Velicelebi , et al. September 3, 2	2013-09-03
Compounds That Modulate Intracellular Calcium App 20120289587 - Velicelebi; Gonul ; et al.	2012-11-15
Compounds that modulate intracellular calcium Grant 8,263,641 - Velicelebi , et al. September 11, 2	2012-09-11
Compounds That Modulate Intracellular Calcium App 20090137659 - VELICELEBI; Gonul ; et al.	2009-05-28
Substituted heterocycles for the treatment of diabetes and other diseases Grant 7,226,940 - Pfahl , et al. June 5, 2	2007-06-05
Heterocyclic derivatives for the treatment of cancer and other proliferative diseases Grant 7,153,875 - Pfahl , et al. December 26, 2	2006-12-26
N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases App 20060160796 - Pfahl; Magnus ; et al.	2006-07-20
N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases Grant 7,071,218 - Pfahl , et al. July 4, 2	2006-07-04
Substituted heterocycles for the treatment of diabetes and other diseases App 20060004059 - Pfahl; Magnus ; et al.	2006-01-05
Imidazolidinedione derivatives for the treatment of diabetes and other diseases Grant 6,974,826 - Pfahl , et al. December 13, 2	2005-12-13
RXR activating molecules App 20050209286 - Pfahl, Magnus ; et al.	2005-09-22
Imidazolidinedione derivatives for the treatment of diabetes and other diseases App 20050070581 - Pfahl, Magnus ; et al.	2005-03-31
Thiazolidinedione derivatives for the treatment of diabetes and other diseases Grant 6,765,013 - Pfahl , et al. July 20, 2	2004-07-20
2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer App 20040097566 - Pfahl, Magnus ; et al.	2004-05-20
Thiazolidinedione derivatives for the treatment of diabetes and other diseases App 20030153606 - Pfahl, Magnus ; et al.	2003-08-14
N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases App 20030144329 - Pfahl, Magnus ; et al.	2003-07-31
RXR activating molecules App 20030105333 - Pfahl, Magnus ; et al.	2003-06-05
Heterocyclic derivatives for the treatment of diabetes and other diseases Grant 6,515,003 - Pfahl , et al. February 4, 2	2003-02-04
Heterocyclic derivatives for the treatment of cancer and other proliferative diseases App 20020143182 - Pfahl, Magnus ; et al.	2002-10-03

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.